VolitionRx — Building real-world Nu.Q NETs sepsis data

Volition continues to build data demonstrating that the Nu.Q® NETs H3.1 diagnostic platform is a potential breakthrough tool in sepsis management. These efforts underpin Volition’s aim to advance Nu.Q NETs as a rapid, accessible and accurate diagnostic test to manage this potentially devastating condition. Sepsis (immune system triggered organ dysfunction) affects c 50 million people a year worldwide, and results in c 11 million deaths. Further, every hour of delayed treatment raises the mortality risk by c 8%. In this note we review Volition’s recent updates from the ESICM Annual Congress, where it provided evidence across data comprising more than 3,000 patients that its technology can quickly and reliably detect the patients most at risk of mortality, septic shock and organ failure. Improving the identification and tracking of at-risk patients should help improve treatment paradigms.